Gilead announced a partnership with Alphabet’s Verily Life Science. The biotech start-up will run tests on white bl… https://t.co/3VzDGQ69Oq
RT @MaxJacobsEdison: HCV sales for $GILD are down 59% year over year and 30% sequentially. When did big biotech earnings get so depressing…
RT @BiotechRadar: Galapagos $GLPG / Gilead $GILD: filgotinib-related catalysts Q1 2018 update,
slight shifts https://t.co/4g89fCna3B
Gilead Sciences $GILD Releases Earnings Results, Misses Expectations By $0.19 EPS https://t.co/LyYFTl35S6
Gilead Sciences $GILD Announces Earnings Results, Misses Expectations By $0.19 EPS https://t.co/ecPLdoCMZ0
RT @matthewherper: $GILD seeing good reimbursement for Yescarta in both commercial and Medicare populations.
2013 interview question with Lori M. Waldron Member of Life Sciences practice group responding to a troubling BigPh… https://t.co/kxh6CYi0bf
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @JohnCendpts: #3
Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology
$GILD
https://t…
So let’s see now $mrk $pfe & $gild all have declining revenue, and All also have hardly any pipeline/ R an D left.… https://t.co/Nl0E3xrVfo
$GILD $1.046B HCV is better than Mavyret ever did.
$GILD from block buster to block duster . ..falling sales and they bought $KITE to do what
Gilead Q1 revenue, profit miss estimates, as hepatitis C drug sales more than halve https://t.co/7fEYHDegyL $GILD #pharma
RT @RobertLKruse: "Based on current HCV management practices, it will take 4-6 years to treat the majority of patients aware of their disea…
"Based on current HCV management practices, it will take 4-6 years to treat the majority of patients aware of their… https://t.co/Gs1VtLG2gw
$GILD https://t.co/CXVPXAVBjw
$GILD never fails to disappoint.. misses expectations. #figureitout $IBB $XBI #investing #biotech #healthcare
Gilead topples as its hepatitis C drug franchise continues to crumble $GILD https://t.co/Jtp7N5pMUA
@Lblegend33 Market share... everyone saw this coming except $gild mgmt apparently and they didn’t set themselves up to overcome this
Incredible chart. That said, still so many patients out there remain to be cured of #HCV and with a huge market.… https://t.co/2qETaSsncO
RT @TradeTexasBig: $GILD 68.. buyzone 64 to 66.. as long as they have cash..
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
JPM got it right $GILD https://t.co/gFqqkYGDRR
$gild=RIP
$GILD 68.. buyzone 64 to 66.. as long as they have cash..
@ScripMandy Same old story. $GILD said the same before buying $KITE. "We're going to stick to our NASH pipeline" and then it came the BO
RT @ai_autonomous: Perelman AI Algorithm Crashes Gilead Sciences on Multi-Billion Profit $GILD #biotech #earnings #AI #perelman https://t.c…
RT @ai_autonomous: Perelman AI Algorithm Crashes Gilead Sciences on Multi-Billion Profit $GILD #biotech #earnings #AI #perelman https://t.c…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
Perelman AI Algorithm Crashes Gilead Sciences on Multi-Billion Profit $GILD #biotech #earnings #AI #perelman… https://t.co/g3WHUTn1Bx
RT @CaesarBiotech: $GILD Confirmation on Q1 slides: Gilead hbv pipeline is on attrition phase despite Milligan said last year that their ma…
That said, $GILD popped after the KITE pharma acquisition but then declined thereafter - as if the acquisition was… https://t.co/UYRxXT66q9
Gilead Sciences $GILD Announces Earnings Results, Misses Expectations By $0.19 EPS https://t.co/DwbKSIj60b
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @Jdalexander64: $GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opportunity…
AI Perelman Algorithm Crashes Gilead Sciences on Multi-Billion Profit $GILD: https://t.co/kPrnUAaHkZ via @YouTube
$GILD was usually pitched with "buy it for the HIV business - get HCV business for free". With Harvoni sales in %74… https://t.co/yEu5sYAYOC
My second "Am I reading this right?" of the day: $GILD has $32B in cash & cash equivalents? Is it time to go shopping?
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @FayCortez: Small bright spot for $GILD on Yescarta - blowing past the $16 million estimate from analysts with a $40 million first full…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @EpiscopalianTra: $GILD At this rate, this company will be an acquiree, not acquirer.
I'd go in at around $63
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
$GILD At this rate, this company will be an acquiree, not acquirer.
I'd go in at around $63
$GILD stock down -5.60% after hours, stock continues to slide since last year Q1. See our past data recap https://t.co/2HGBRABCBQ
$GILD Robin Washington keeps saying “we’re comfortable with where we are” but investors clearly not. Down 5.6% after hours at $68.50.
$GILD seeing good reimbursement for Yescarta in both commercial and Medicare populations.
Unicorn Bay rating for $GILD is 2.79 out of 5. https://t.co/jD70zGcNYE
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to t… https://t.co/NVXoH6Xdm5
$GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opport… https://t.co/nbgqZlYKzL
$Gild earnings https://t.co/JFVnt6KXib
RT @FayCortez: Small bright spot for $GILD on Yescarta - blowing past the $16 million estimate from analysts with a $40 million first full…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
The stock market is always ready, are you? $AAPL $SNAP $MTCH $GILD https://t.co/BeLiyDZQtp https://t.co/debWlHtsTZ
@pawcio2009 Go nuts xbi doesn’t matter and most of ours in xbi. who cares about ibb big cap Pharm and $gild
$GILD Down 4.9% in After Hours Trading.
Gilead Sciences
Valuation, Profitability, and Dividend Safety Scores.
Stock… https://t.co/cZVAXsaSTl
#3
Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology
$GILD
https://t.co/austsLDo3T
RT @AndyBiotech: $GILD Yescarta Q1 sales $40M beat consensus of $16M (though buyside expectation higher after $NVS Kymriah number and WSJ s…
Gilead $gild stabilizing as we work through the beginning of the Q&A portion on the call. Will be interested to see… https://t.co/0WeakrbKL7
$GILD revenues in free fall adapt or become obsolete https://t.co/19vvaTnqbY
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @FayCortez: Small bright spot for $GILD on Yescarta - blowing past the $16 million estimate from analysts with a $40 million first full…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @Lblegend33: So let’s see now $mrk $pfe & $gild all have declining revenue, and All also have hardly any pipeline/ R an D left. Yet they…
RT @eWhispers: #earnings after the close
$AAPL $SNAP $GILD $COHR $TMUS $PAYC $DVN $SU $WATT $APC $BGFV $JNPR $MDLZ $ALL $FTR $WU $MDLP $CH…
Access tools built by 10% traders for 10% traders $MTCH $GILD $AAPL $SNAP https://t.co/BeLiyDZQtp https://t.co/HGy1GvSgwo
Post Mkt Gappers/Crappers $NANO $CRAY $SFLY $ZEN $EVTC $AAPL $SNAP $YUMC $GILD $PAYC $SKT $KR
Try our FREE chat… https://t.co/g0P8eKAadM
Can $NVO, $AZN and $CELG change the tone on a generally bleak Q1 earnings period? https://t.co/zaWw0JlIKr $GILD $MRK $PFE
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
$sgmo did $gild confirm anywhere that they did purchase 50 million$ of $sgmo shares on $sgmo BS stock offering ?? asking ??
$GILD 04-May-18 ATM Implied Vol Jumps +11.3% to 51.7. Straddle Implies a Move of ±4.5% https://t.co/ZQOfhHMvOD
I’ve been describing $GILD HCV cure as revenue cliff for years since incidence was tiny and prevalence would declin… https://t.co/rkdHDDhac5
@TradeWithNinja $GILD missed
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
▶ Stock Selection By Using AI & Machine Learning: Top 10 Stocks For May + Top 20 Tech Stocks...… https://t.co/QtYzPRCOZq
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymr… https://t.co/tBPa10HfTr
$GILD what a disaster
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @sesiegler: @cells_nnm @bradloncar @JacobPlieth @matthewherper @BLLPHD @AndyBiotech @MaverickNY Also, they filed a NTAP for FY2019. @CM…
$GILD Q1 total product sales -22% YoY
HCV sales -59% YoY
HIV + HBV sales +2% YoY
other product sales +17% YoY
@cells_nnm @bradloncar @JacobPlieth @matthewherper @BLLPHD @AndyBiotech @MaverickNY Also, they filed a NTAP for FY2… https://t.co/o2coerlbxZ
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
After Hours Gainers / Losers (05/01/2018) $SIGA $CYH $SFLY $ENPH $FTR $SNAP $YUMC $LPI $SKT $GILD https://t.co/9jnlypbI5r
Stocks making the biggest moves after hours:
$SNAP $AAPL $GILD
Snap, Apple, Gilead & more - https://t.co/MNNaxmU3rr
Gilead Sciences $GILD Announces Quarterly Earnings Results https://t.co/9TaTQ0FOnm
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
I hear the nurse was a distraught $GILD shareholder. https://t.co/T2qTUcir0y
Not the best timing for $GILD just as they finish explaining how Yescarta launch is going well and as they planned… https://t.co/IXa670s7S3
Nice call. $GILD https://t.co/G9kXo2mUSZ
Gilead Sciences $GILD Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS https://t.co/d0T6Suavrh
RT @AndyBiotech: $GILD Yescarta Q1 sales $40M beat consensus of $16M (though buyside expectation higher after $NVS Kymriah number and WSJ s…
@cells_nnm @bradloncar @JacobPlieth @matthewherper @BLLPHD @AndyBiotech @MaverickNY There’s competition now for thi… https://t.co/fFgBENGit8
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @JohnCendpts: #3
Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology
$GILD
https://t…
RT @7LadyQ: $GILD
Gilead Sciences misses by $0.19, misses on revenue
Gilead Sciences (NASDAQ:GILD): Q1 EPS of $1.48 misses by $0.19.
Revenu…
$GILD slide from Aug 2017 vs May 2018 (h/t: @MaxJacobsEdison)
Their HCV trend never changed. It keeps.going.down.… https://t.co/twko2HFdRc
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
ICYMI. $BLUE $GILD https://t.co/SRmF829Hwm
$GILD Yescarta revs went from $7M in Q4 2017 to $40M in Q1 2018 - a 500% jump QoQ. Novartis Kymriah only $12M.
After Hours Movers: $SFLY $CRAY $ACTG $ZEN $BGFV $JNPR $AAPL $SNAP $GILD https://t.co/8mrT5SACLU
Weekly Stock Market Review: Top 10 Stock Picks For May: https://t.co/6I1fM213GR
$SPY $AAPL $AMZN $MSFT $AMD… https://t.co/Crvpc5hJK4
@zbiotech @adamfeuerstein Approval of Yescarta competitor ( $NVS 's Kymriah) for r/r B-Cell Lymphoma is good news f… https://t.co/VfWN8815I8
HCV sales ex-US have *always* been more competitive for $GILD. Mgmt thinks pricing and share will stabilize in 1-2… https://t.co/Hd9poAmFUz
$GILD:
Gilead Topples As Its Hepatitis C Drug Franchise Continues To Crumble:
https://t.co/X1DKSAD6Cn
RT @FZucchi: @JPM63887712 They are spending $12B/yr in R&D as it is; that's just shy of what $GILD $AMGN & $MRK spend...combined...and they…
@StockTwits Trending via @Stocks_Live #stocks #stockmarket $AAPL $SNAP $GILD $MTCH $I $WATT $SHOP $MA $BSTI $TMUS… https://t.co/6qZCYWjC8m
Jim Cramer Mad Money Lightning Round https://t.co/iCW9mIHGyw $AMAT $JEC $GERN $REGN $GILD $NVDA $CGNX $BOX $EDIT $CELG $GT @jimcramer @cnbc
Gilead Sciences $GILD settled +0.4% at $72.56. With a sig' EPS/rev' miss, as at 7.10pm EST, the stock is -5.7% at $… https://t.co/IQvvDCshgE
RT @bradloncar: Huge week of earnings coming up.
M: $AGN $NBIX
T: $GILD $INCY $IRWD $MRK
W: $EXEL $NVO $UTHR
T: $ALNY $REGN $SAGE $SRPT
F:…
$TEVA settled +4.1% at $18.71, above the 200/50dmas. Further, the m/t bearish trend from 2015 concluded today. Earn… https://t.co/Nn8bcA74v5
@golf_stock_life If they don’t beat, PPS will get crushed like $GILD (who for some reason decides not to talk about… https://t.co/NvP8iMNKag
@CGrantWSJ Down goes @jimcramer 's charitable trust and prolly his own shill account. $GILD BTW, throw out a posi… https://t.co/YHEVlNGxRG
$GILD announced a 0.57 dividend. Annual Yld is 3.1%. GILD raised its dividend 3 times in 3 yrs. https://t.co/swXYzZECu8
AbbVie $ABBV settled +5.7% at $102.07, as the company is seeking to buy $7.5bn of its stock back. The stock is chal… https://t.co/s5Wo2vfWcG
RT @Jdalexander64: $GILD press release - only $SGMO
Oncology and Cell Therapy Programs
Announced a worldwide collaboration with Sangamo Th…
@zipjet Yes
My expectation was that a good part of the cash generated would be used for M&A.
$GILD was too timid with a poor strategic view
▶ Stock Selection By Using #AI & Machine Learning:Top 10 Stocks For May + Top 20 Tech Stocks...… https://t.co/01ETG9vuvm
Three huge mistakes $GILD has made.
1) Curing HCV
2) Stock Buybacks
3) Curing HCV
RT @TradersFish: $GILD stock down -5.60% after hours, stock continues to slide since last year Q1. See our past data recap https://t.co/2HG…
Gilead Sciences $GILD Posts Quarterly Earnings Results, Misses Estimates By $0.19 EPS https://t.co/zp6PA8WSia
$SNAP ohhhhhhhh #SNAP ... (Also $YUMC $GILD $SKT $PAYC $LPI $COHR etc.. ready for some lucrative SHORTING tomorrow!… https://t.co/KAGTQZoPAM
@DewDiligence It will be fun to watch when the $ENTA HepC party ends. Like $GILD, it ends. When it does, will $ENTA… https://t.co/4VzMOsS7ni
STOP trading randomly, get the best opportunities and profit everyday $AAPL $SNAP $GILD $MTCH… https://t.co/gTwA2Fh7eS
RT @AndyBiotech: $GILD HCV franchise Q1 total sales $1,046M misses consensus of $1,175M
US: $584M vs. $674M cons
ex-US: $462M vs. $501M…
RT @FayCortez: Small bright spot for $GILD on Yescarta - blowing past the $16 million estimate from analysts with a $40 million first full…
RT @Jdalexander64: $GILD press release - only $SGMO
Oncology and Cell Therapy Programs
Announced a worldwide collaboration with Sangamo Th…
RT @BursatilBiotech: $GILD slide from Aug 2017 vs May 2018 (h/t: @MaxJacobsEdison)
Their HCV trend never changed. It keeps.going.down.
Ri…
Ugly qtr for $GILD -no two ways about it - HIV miss.. HCV miss and if the execs are comfortable bcuz of the 12 bill… https://t.co/gBzS7st4Sy
Sadly, they are well on their way, and things are likely to get worse between the new #CARTcell competition for DLB… https://t.co/SWPTgsn0nN
@JorelLaraKalel @jimcramer @CNBC At least $GILD, $CELG, and $REGN are in the same business as $GERN (unlike $ILMN,… https://t.co/rEvRxQKr31
After-Hours Stock Movers 05/01: $CRAY $CYH $AAPL Higher; $SNAP $YUMC $GILD Lower more... https://t.co/17k4roKVx8
Wednesday: $I, $AAPL, $TSLA, $TTWO, $IAC, $NOC, $GILD, $FB
RT @Jdalexander64: $GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opportunity…
@Sport234a Remember, years ago, when $GILD execs sarcastically asked analysts to let them know what they should buy… https://t.co/Z7GzzMUZG8
GILD pounded after the bell(-5.5%/earnings), headed for huge downside gap, will open well into fresh new '18 low te… https://t.co/hOsbJiT8Cb
@BTLipschultz @GreenMonsterah I don’t see $gild nash drug being a real threat in the nash space imho.
RT @FayCortez: Small bright spot for $GILD on Yescarta - blowing past the $16 million estimate from analysts with a $40 million first full…
$GILD Daily, weekly, and monthly support levels to get back on trend. https://t.co/6VEmzYbgdh
RT @BTLipschultz: Gilead $gild stabilizing as we work through the beginning of the Q&A portion on the call. Will be interested to see if th…
RT @AndyBiotech: $GILD HCV franchise Q1 total sales $1,046M misses consensus of $1,175M
US: $584M vs. $674M cons
ex-US: $462M vs. $501M…
RT @jonathanrockoff: $NVS says @US_FDA has approved Kymriah for use in adults with advanced large B-cell lymphomas, intensifying the CAR-T…
RT @JohnCendpts: #3
Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology
$GILD
https://t…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @BursatilBiotech: $GILD slide from Aug 2017 vs May 2018 (h/t: @MaxJacobsEdison)
Their HCV trend never changed. It keeps.going.down.
Ri…
RT @MaxJacobsEdison: Sometimes nothing seems to go right $GILD https://t.co/6wxyleXJfu
$GIlD So when Sovaldi was approved on Dec 6 2013 share price was 73.99
How did Gilead investors get rich off Hep C… https://t.co/S3R7bHrI0v
$GILD https://t.co/kDXnBC2pOQ
$GILD https://t.co/8YmfbAzbOO
Biotech updates 05/01:
$NVS Kymriah 2nd approval
$SIGA +ve adcom vote
$KPTI $QURE offerings
+ Pipeline updates… https://t.co/Ka1p6eFNi1
@YGPharmaAnalyst $GILD bruh. Yikes!! Still modeling $100+?
Beat the market with the Ideal Intensity Indicator, the only indicator you need $AAPL $SNAP $GILD $MTCH… https://t.co/3n6KazHF3b
Impressive when on company focuses on cures vs palliation and symptom control. Congrats $GILD @GileadSciences https://t.co/rYRK3uBvbl
@JekyllMorgan @timseymour Its a good acquisition, but those drugs aren't curing anyone yet... Time will tell. Same… https://t.co/E87jhefam8
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
Btw, Estimated #Earnings Per Share for $GILD is $1.92 it's 2.66% of the current price https://t.co/ITADQ4KDmZ
Get FREE Tools to manage emotions, reduce randomness, and risk mgt w/ Membership $GILD $MTCH $AAPL $SNAP… https://t.co/wf1hAQHuod
RT @Jdalexander64: $GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opportunity…
RT @Jdalexander64: $GILD press release - only $SGMO
Oncology and Cell Therapy Programs
Announced a worldwide collaboration with Sangamo Th…
RT @CompoundTrading: Post-Market Trading Report Tues May 1. $HTBX, $SNAP, $AAPL, $GILD, $APVO, $EOG, $ATHM, $CHECK, $DXY more… https://t.co…
Losing $$$ trading? Get help: ISW finds opportunities in Real-time+Live Chat $GILD $MTCH $AAPL $SNAP… https://t.co/3QYZnDMmXS
Post-Market Trading Report Tues May 1. $HTBX, $SNAP, $AAPL, $GILD, $APVO, $EOG, $ATHM, $CHECK, $DXY more…… https://t.co/AfKkcK2Ldc
Don't miss our next FREE OPTION TRADE. Sign up for our Daily Free Trades at https://t.co/v1csoSCfrS $NVDA $TSLA $GS $GILD $F $GOOGL $FB
RT @Jdalexander64: $GILD press release - only $SGMO
Oncology and Cell Therapy Programs
Announced a worldwide collaboration with Sangamo Th…
@Sport234a Another reminder- $GILD share repurchases were about as crappy an investment as a company could make.
RT @Jdalexander64: $SGMO wasn't my favorite pick although it went from $4 to $26, but now w 40% decline, even as signals materialize that t…
Missing out on amazing trades? ISW scanner streams right to your desktop $AAPL $SNAP $GILD $MTCH… https://t.co/PWo0FSpgRo
RT @SA_BioTech: $ABBV $AGEN $AMGN $AZN $BMY $CELG $GILD $GSK $JNJ $JUNO $LLY $MRK $NVS $PFE $REGN $SNY $EVLO https://t.co/ZbUYz8WYJI
$GILD $BIIB $CELG $REGN $INCY I don't even own a PS4 but I think this is how investors feel towards the clowns runn… https://t.co/gVJ3ihaDzU
RT @crusadernz: Biotech updates 05/01:
$NVS Kymriah 2nd approval
$SIGA +ve adcom vote
$KPTI $QURE offerings
+ Pipeline updates $GILD $GLPG…
RT @crusadernz: Biotech updates 05/01:
$NVS Kymriah 2nd approval
$SIGA +ve adcom vote
$KPTI $QURE offerings
+ Pipeline updates $GILD $GLPG…
$GILD i'll probably buy some down here
Tired of the stock market rollercoaster? Use it to your advantage� $GILD $MTCH $AAPL $SNAP https://t.co/BeLiyDZQtp https://t.co/t76RPGCBl1
RT @AndyBiotech: $GILD HCV franchise Q1 total sales $1,046M misses consensus of $1,175M
US: $584M vs. $674M cons
ex-US: $462M vs. $501M…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @MattBurns25: Weekly Stock Market Review: Top 10 Stock Picks For May: https://t.co/6I1fM213GR
$SPY $AAPL $AMZN $MSFT $AMD $NVDA $ABX…
RT @Jdalexander64: $GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opportunity…
@BehaviorFin @Jdalexander64 8am is early for west coast companies. Last time $SGMO had an early EC they announced $GILD deal...
Not sure what to do with $GILD? Explore our #fundamental pros and cons. https://t.co/NgREtgOwQu
RT @SA_BioTech: $GILD https://t.co/kDXnBC2pOQ
$GILD back to pre $KITE levels. More acquisitions soon?
$GILD declines in after hours trading. See the latest news. https://t.co/UTiq6dErsp https://t.co/X9jn5W3MP5
Struggling with Trading? Members get full access to Training Center - FREE $AAPL $SNAP $GILD $MTCH… https://t.co/og5T2OcdR0
Gilead joins the lineup of big #biopharma partners to ally with Verily — this time focused on #immunology https://t.co/uio34iZXDg $GILD
$GILD These clowns can easily acquire other companies and expand the portfolio of offerings but NOPE
RT @NASDboy: $GILD Another one to cheer everyone up $SNAP courtesy of @bagholderquotes https://t.co/CmKVbiPPao
RT @NASDboy: $GILD just stopping by to post a few GIFS don’t mind me $SNAP https://t.co/dM8av5CF5k
End of an era $GILD https://t.co/XMZwk9Rz2w
Do you know that #Book Value for $GILD is $15.63 https://t.co/dYpmlEXDNp
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @businessinsider: A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved to trea…
Not going to be a pretty day tomorrow. $GILD. < One bio that I actually like. https://t.co/GSCAZGhPZK
RT @ArabicWallSt: .
هذا الاسبوع ناري باعلانات ارباحه
.
الاثنين - $MCD $AKS $RIG $AGN $AKAM $FDC
الثلاثاء - $AAPL $SNAP $GILD $SHOP $PFE $BP…
RT @permabear_uk: Gilead Sciences $GILD settled +0.4% at $72.56. With a sig' EPS/rev' miss, as at 7.10pm EST, the stock is -5.7% at $68.40.…
Night Most Tweeted Big Caps, check out Gambiste Top 10: $GILD $ISRG $FB $AAPL $GOOGL $GOOG $AMZN https://t.co/lYp5LtitVR
Streaming alerts, Live chat, Pre-Mkt, After-Mkt, Bear scan for active traders $AAPL $SNAP $MTCH $GILD… https://t.co/LhD2HIsiAK
Wondering about risks of $GILD? The 21-day volatility is 5.5% https://t.co/YrfwPBdUuU
Btw, Estimated #Earnings Per Share for $GILD is $1.92 it's 2.65% of the current price https://t.co/ITADQ4KDmZ
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
Credit Suisse Maintains a Hold Rating on Gilead Sciences $GILD https://t.co/hMEQc0JzdU
RT @MaxPowerNGS: @BehaviorFin @Jdalexander64 8am is early for west coast companies. Last time $SGMO had an early EC they announced $GILD de…
$GILD - when you cure a disease, you better have something else in the pipeline.
Time to throw in the towel ? Sell… https://t.co/I21OQfr42q
$GILD honestly their is no reason to buy or own this stock right now. Company is on the decline at a fast rate. Revenue down over 2 billion
Ideal Intensity Indicator [I^3] - Optimize Entries and Exits for more $$$ $GILD $MTCH $AAPL $SNAP… https://t.co/rVBaKREnIu
$GILD They need to acquire another company to offset the sales loses. It will take years for kite deal to pay off.
RT @permabear_uk: $TEVA settled +4.1% at $18.71, above the 200/50dmas. Further, the m/t bearish trend from 2015 concluded today. Earnings a…
$AMGN $CELG $GILD lack of growth is incredible
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
earlier:
SOLD - $GILD MAY25'18 $67 PUT for $0.6721/share. In force 25 days. 15.26% annualized premium return. After… https://t.co/XRTwaAab9j
$GILD 04-May-18 ATM Implied Vol Jumps +11.3%. Straddle Implies a Move of ±4.5% https://t.co/ZQOfhHMvOD
$GILD HCV sales are collapsing... Down %59 YoY... https://t.co/fkIfuHdByd
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @BursatilBiotech: $GILD - Yescarta Sales Q1
$40M vs $16M consensus
@Arie_Belldegrun , still the #1 https://t.co/HD26c8DDYl
RT @AndyBiotech: $GILD Yescarta Q1 sales $40M beat consensus of $16M (though buyside expectation higher after $NVS Kymriah number and WSJ s…
$GILD Option Order Flow Sentiment has Shifted from Bullish to Bearish. https://t.co/sD9L6tOUzF
$AAPL $GILD $SNAP After-hours buzz: SNAP, AAPL, GILD & more https://t.co/Siycp7zH3x
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @Jdalexander64: $GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opportunity…
RT @GaryThomson16: ▶ Stock Selection By Using AI & Machine Learning: Top 10 Stocks For May + Top 20 Tech Stocks... https://t.co/963bxUm7ca…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
RT @MarketCurrents: Gilead Q1 top line down 22%; earnings down 43%; shares down 6% after hours https://t.co/ilnn5NTjxF $GILD
Recommendation #HOLD for $GILD with UB rating - 2.79 out of 5. https://t.co/Kn4eAPYUj7
$GILD #Buybacks https://t.co/KXHR4uj8qa
John Francis Cogan Sells 5,833 Shares of Gilead Sciences $GILD Stock https://t.co/SpDp4yABsy
RT @JacobPlieth: If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17 https://t.co/Q…
RT @bradloncar: $GILD HCV sales over time. Credit to them for curing so many patients.
Now moving on and aiming to do the same for cancer…
@matthewherper And let’s also mention that all of these developments are slaps in the face if autologous cell thera… https://t.co/dtXTBJTCI0
RT @JacobPlieth: If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17 https://t.co/Q…
RT @JacobPlieth: If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17 https://t.co/Q…
If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17… https://t.co/x3GQw6COwp
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
Gilead Sciences $GILD Lowered to “Buy” at ValuEngine https://t.co/6v62rXGXWj
RT @blockcha1nx: $GILD releasing a dividend @ 60% payouts w yield >3%, on a stock w shareholders w 0 loyalty, & earnings that will go down…
$GILD releasing a dividend @ 60% payouts w yield >3%, on a stock w shareholders w 0 loyalty, & earnings that will g… https://t.co/7gskLStEP1
PharmaScrip: $ABBV Up slightly after $GILD 1Q18 release. https://t.co/JfQn0m31uZ … https://t.co/XeTlcqGrvj https://t.co/TWDSGvEWe3
RT @ScripMandy: $ABBV Up slightly after $GILD 1Q18 release. https://t.co/ssv5gYOlfo
Baird $GILD
Gilead Sciences, Inc. (GILD)
Ugly 1Q Raises Questions About What Trough Looks Like
Lowering target pri… https://t.co/A4aj573psG
I Got an Email From Someone. Here's What They Had to Say About #Allergan 's Chairman & CEO Saunders $aapl $amzn… https://t.co/SOMIXzL2Sg
@tgtxdough Mizhou must own a lot of $gild stock, cause this thing is garbage
MIZHOU $GILD Buy, PT: $95.00,
1Q18 Call Takeaways + Spoke to Company ==> HIV Concerns Overblown, HCV Some Risk We Think
RT @JacobPlieth: If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17 https://t.co/Q…
RT @JacobPlieth: @VinayPrasadMD ...ditto for Yescarta. Label cites n=101 as denominator, not =111 (ITT in Zuma-1) $GILD https://t.co/lZ9rVy…
Gilead Sciences $GILD Lowered to “Buy” at ValuEngine https://t.co/31WsMhpZrz
RT @Lblegend33: Another bio misses on revenue $mrk. Don’t worry tho keep doing the same thing and it will miraculously change. $gild you’re…
PharmaScrip: $GILD Down 5+% after hours after reporting $5.1bn in 1Q18 revenue vs consensus of $5.4bn. EPS $1.48 b… https://t.co/55iZQsSm8p
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
@VinayPrasadMD ...ditto for Yescarta. Label cites n=101 as denominator, not =111 (ITT in Zuma-1) $GILD https://t.co/lZ9rVyyT86
RT @ScripMandy: $GILD Down 5+% after hours after reporting $5.1bn in 1Q18 revenue vs consensus of $5.4bn. EPS $1.48 below consensus of $1.6…
▶ Stock Selection By Using #AI & Machine Learning: Top 10 Stocks For May + Top 20 Tech Stocks...… https://t.co/f56BaPEBLw
RT @AndyBiotech: $GILD Yescarta Q1 sales $40M beat consensus of $16M (though buyside expectation higher after $NVS Kymriah number and WSJ s…
RT @vieiraUAE: Perelman's AI Trading Algorithm Crashes Gilead Sciences, Micron, and Snapchat $MU $SNAP $GILD #biotech #earnings #snapchat #…
RT @vieiraUAE: Perelman's AI Trading Algorithm Crashes Gilead Sciences, Micron, and Snapchat $MU $SNAP $GILD #biotech #earnings #snapchat #…
Perelman's AI Trading Algorithm Crashes Gilead Sciences, Micron, and Snapchat $MU $SNAP $GILD #biotech #earnings… https://t.co/aEjChW9KT3
$SPY $QQQ $AAPL $AMZN $FB $FPKT $FUJIY $GE $GILD $IAC $LUV $MDLZ $MRK $PFE $RUALF $SAFRY $SNAP $SSNLF $TMUS $UAA https://t.co/UxxJslrlPR
RT @SeekingAlpha: $SPY $QQQ $AAPL $AMZN $FB $FPKT $FUJIY $GE $GILD $IAC $LUV $MDLZ $MRK $PFE $RUALF $SAFRY $SNAP $SSNLF $TMUS $UAA https://…
$SPY $QQQ $AAPL $AMZN $FB $FPKT $FUJIY $GE $GILD $IAC $LUV $MDLZ $MRK $PFE $RUALF $SAFRY $SNAP $SSNLF $TMUS $UAA https://t.co/iF9chF7RlT
RT @ScripMandy: $ABBV Up slightly after $GILD 1Q18 release. https://t.co/ssv5gYOlfo
Cramer's lightning round: $AMAT $JEC $GERN $REGN $GILD $NVDA $CGNX $BOX $EDIT $CELG $GT https://t.co/TRUk9ky7Gt
Lotsa health care earnings this am: $HUM up 1.6%, $CVS up 3% and $ABC up 2.2%. Plus $GILD down 6% after reporting after hours ytd.
RT @Benzinga: 16 Stocks To Watch For May 2, 2018 https://t.co/UicGXSgIAh $AAPL $ABC $ADP $CVS $EXC $MA $PRU $HUM $SNAP $ESRX $TSLA $GILD $M…
RT @Benzinga: 16 Stocks To Watch For May 2, 2018 https://t.co/UicGXSgIAh $AAPL $ABC $ADP $CVS $EXC $MA $PRU $HUM $SNAP $ESRX $TSLA $GILD $M…
RT @Benzinga: 16 Stocks To Watch For May 2, 2018 https://t.co/UicGXSgIAh $AAPL $ABC $ADP $CVS $EXC $MA $PRU $HUM $SNAP $ESRX $TSLA $GILD $M…
RT @imriyu: @tgtxdough $GILD also have $25B in debt..
16 Stocks To Watch For May 2, 2018 https://t.co/UicGXSgIAh $AAPL $ABC $ADP $CVS $EXC $MA $PRU $HUM $SNAP $ESRX $TSLA $GILD $MET $SFLY $KHC
RT @tgtxdough: $GILD Gilead has roughly $32B in cash on the balance sheet to do deals. But free cash flow down significantly https://t.co…
RT @adamfeuerstein: $GILD ‘trough year’ looking harder to dig out from after miserable first quarter https://t.co/5gQlwcQvjh
$ABEO $ADMS $ALXN $ARRY $ATRS $BLUE $BPMC $CORT $DVAX $EXEL $GILD $GLPG $GSK $HCM $IBB $IONS $NBIX $NVCR $NVS $XBI… https://t.co/DGdIZnlxYM
Unicorn Bay rating for $GILD is 2.79 out of 5. https://t.co/jD70zGcNYE
$GILD ‘trough year’ looking harder to dig out from after miserable first quarter https://t.co/5gQlwcQvjh
$gild another disappointing quarter. Yet reiterates guidance unfortunately long this name for a long time #dead $
RT @tgtxdough: $GILD Gilead has roughly $32B in cash on the balance sheet to do deals. But free cash flow down significantly https://t.co…
$GILD declines in premarket trading. See the latest news. https://t.co/1UjNVlruPT https://t.co/QW8xONsmql
RT @KlendathuCap: @SuperMugatu $GILD just gilding things bro.
@tgtxdough $GILD also have $25B in debt..
RT @tgtxdough: $GILD Gilead has roughly $32B in cash on the balance sheet to do deals. But free cash flow down significantly https://t.co…
$GILD Gilead has roughly $32B in cash on the balance sheet to do deals. But free cash flow down significantly https://t.co/2Gj0J3env5
RT @CaesarBiotech: $GILD Confirmation on Q1 slides: Gilead hbv pipeline is on attrition phase despite Milligan said last year that their ma…
Perelman's AI Trading Algorithm Crashes Gilead Sciences, Micron, and Snapchat $MU $SNAP $GILD #biotech #earnings… https://t.co/pJkHYCfgc9
RT @tgtxdough: MS $GILD Underlying HIV demand was strong (+12%), but inventory was a headwind. While we expect GILD down, we believe underl…
MS $GILD Underlying HIV demand was strong (+12%), but inventory was a headwind. While we expect GILD down, we belie… https://t.co/lX90RLaygU
RT @tgtxdough: MIZHOU $GILD Buy, PT: $95.00,
1Q18 Call Takeaways + Spoke to Company ==> HIV Concerns Overblown, HCV Some Risk We Think
RT @tgtxdough: Baird $GILD
Gilead Sciences, Inc. (GILD)
Ugly 1Q Raises Questions About What Trough Looks Like
Lowering target price to $79…
RT @tgtxdough: Baird $GILD
Gilead Sciences, Inc. (GILD)
Ugly 1Q Raises Questions About What Trough Looks Like
Lowering target price to $79…
Watchlist $GILD $AAP $PSA $CAT https://t.co/q59FitNr7p
16 Stocks To Watch For May 2, 2018 $AAPL $ABC $ADP $CVS $EXC $MA $PRU $HUM $SNAP $ESRX $TSLA $GILD $MET $SFLY $KHC https://t.co/bFpbWoJT9D
$SPY $QQQ $AAPL $AMZN $FB $FPKT $FUJIY $GE $GILD $IAC $LUV $MDLZ $MRK $PFE $RUALF $SAFRY $SNAP $SSNLF $TMUS $UAA https://t.co/FZhbSgW2lk
$SPY $QQQ $AAPL $AMZN $FB $FPKT $GE $GILD $IAC $LUV $RUALF $SAFRY $SNAP $SSNLF $UAL $VZ $WMT https://t.co/lX6gf7ojGS
RT @SA_BioTech: $ABBV $AGEN $AMGN $AZN $BMY $CELG $GILD $GSK $JNJ $JUNO $LLY $MRK $NVS $PFE $REGN $SNY $EVLO https://t.co/ZbUYz8WYJI
Morning Most Tweeted Big Caps, check out Gambiste Top 10: $AMD $FFIV $HAS $GILD $ISRG $CELG $CHTR $FB $BKNG $AAPL https://t.co/lYp5LtitVR
Morning Call For Wednesday, May 2 $JNPR $MLM $BRKS $CRAY $NANO $SFLY $AAPL $BGFV $COHR $GILD $SNAP $MTSI $ZEN $YUMC https://t.co/wvK8YmrE9j
Most Active Premarket $SNAP $AAPL $CHK $MU $TVIX $AVGR $AZN $QQQ $UVXY $USLV $SPY $HCHC $S $MA $CNC $HTBX $GILD… https://t.co/wFkYrOJ4CB
21 Stocks Moving In Wednesday's Pre-Market $HCHC $SIGA $SFLY $NANO $JNPR $AAPL $SNAP $HTBX $SSYS $GILD $TAP $W https://t.co/9qG8ONDsc2
$AAPL $SNAP $GILD $CVS $MA $ESPR $HUM $MU $SQ $YUM https://t.co/UEFk6EpO9q
Morning Poppers (The Fat Fuck Edition) - Dr. Fly $AAPL $SNAP $GILD https://t.co/4Gj5Yksh2l
RT @MarketChmln: Top Decliners in #Premarket Hours $SNAP $GILD $TAP $CMI $UGAZ $MU $STX $UN $GOLD https://t.co/sNm3XHVbGw
Top Decliners in #Premarket Hours $SNAP $GILD $TAP $CMI $UGAZ $MU $STX $UN $GOLD https://t.co/sNm3XHVbGw
$SPY $QQQ $AAPL $GILD $CVS $SNAP $TNX #FederalReserve #FOMC #InterestRates https://t.co/HeU8fLAlME
Top 20 $SPY Pre-Market Volume Leaders:
$AAPL $CHK $MU $MA $CNC
$S $GILD $MTCH $AMD $BAC
$GE $FB $INTC $JNPR $SQ… https://t.co/t1DYzoF2fF
$SPY $QQQ $AAPL $AMZN $FB $FPKT $FUJIY $GE $GILD $IAC $LUV $MDLZ $MRK $PFE $RUALF $SAFRY $SNAP $SSNLF $TMUS $UAA https://t.co/afa9Ax5qfW
$GILD $VRX $TPR $MTCH $MS $GS chart https://t.co/5fVpwSVCaK
RT @trade_nut: PRE Market Movers: $CVS $CVX $EL $GRMN $YUM $ADP $GNRC $HUM $APPL $XRX $SNAP $GILD $TMUS $AMZN $MDLZ $TSLA $JNPR $SFLY
PRE Market Movers: $CVS $CVX $EL $GRMN $YUM $ADP $GNRC $HUM $APPL $XRX $SNAP $GILD $TMUS $AMZN $MDLZ $TSLA $JNPR $SFLY
$GILD still down 5% before mrkt open https://t.co/17wI7vuRlY via @business
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings… https://t.co/yoLbCBrdRg
it's not too late to buy $VRTX .....right $GILD? @adamfeuerstein
$GILD PT lowered to $90 from $95 at Barclays
$GILD whicked illustration of the combo of patient warehousing and pricing competition. I knew it'd be quick, but d… https://t.co/GRFdnoMyn5
RT @odibro: $GILD Reiterated with a buy at Jefferies. $95 PT
RT @OpenOutcrier: $GILD (-5.9% pre) Clock Ticks for Gilead as Earnings Miss Sends Shares Falling - BBG Quint
https://t.co/st4mAHNFTD
$GILD (-5.9% pre) Clock Ticks for Gilead as Earnings Miss Sends Shares Falling - BBG Quint
https://t.co/st4mAHNFTD
RT @LTbioinvestor: $GILD $ESPR ... another nice day comng in #biotechs ...
$IBB $XBI
Top 10 $SPY Pre-Market Leaders:
$JNPR $SPGI $PBI $AAPL $ADP
$WYN $CHK $GRMN $TER $MA
Top 10 $SPY Pre-Market Laggar… https://t.co/yQsOyiZDb7
RT @Benzinga: 21 Stocks Moving In Wednesday's Pre-Market Session https://t.co/xNFFLeayAO $HCHC $SIGA $SFLY $NANO $JNPR $AAPL $SNAP $HTBX $S…
RT @SeekingAlpha: $GSK $GLPG $GILD https://t.co/upznNHRozk
$GSK $GLPG $GILD https://t.co/Rf9BydZpsT
$GSK $GLPG $GILD https://t.co/upznNHRozk
Gilead Sciences $GILD Rating Reiterated by Maxim Group https://t.co/XymlMfd3HW
$GILD Reiterated with a buy at Jefferies. $95 PT
Leerink Swann Reaffirms Market Perform Rating for Gilead Sciences $GILD https://t.co/iHRaaa0dpo
21 Stocks Moving In Wednesday's Pre-Market Session https://t.co/xNFFLeayAO $HCHC $SIGA $SFLY $NANO $JNPR $AAPL… https://t.co/fyygnTYNp2
RT @LTbioinvestor: $GILD $ESPR ... another nice day comng in #biotechs ...
$IBB $XBI
RT @AnalystWire: Gilead Sciences $GILD PT Lowered to $79 at Baird https://t.co/BpCri1lcBZ
UP/DOWNGRADES ― $GILD: Maxim Group reits Buy https://t.co/2F1eKgyGd8 via → https://t.co/VS8RO1bzXJ
RT @TradersFish: $GILD stock down -5.60% after hours, stock continues to slide since last year Q1. See our past data recap https://t.co/2HG…
RT @datamonitor_JA: Side by side comparison of Kymriah $NVS and Yescarta $GILD DLBCL labels
CR is much high with Yescarta, though Kymriah…
RT @JacobPlieth: If you're trying to figure out the numbers on Kymriah's US DLBCL label this was the state of play at #ASH17 https://t.co/Q…
RT @TimCarmichael3: $GILD LEERINK-- not cheap enough yet ! Q1 falls short & pipeline depends on crowded RA, price target $80 to $72
RT @tatianadariee: $GILD down 6% pre-market https://t.co/zZ3gTG14kN
RT @BioStocks: $GILD PT lowered to $79 from $87 at Baird
RT @tgtxdough: $GILD Gilead has roughly $32B in cash on the balance sheet to do deals. But free cash flow down significantly https://t.co…
$GILD $ESPR ... another nice day comng in #biotechs ...
$IBB $XBI
$GILD down 6% pre-market https://t.co/zZ3gTG14kN
RT @BioStocks: $GILD PT lowered to $79 from $87 at Baird
RT @BursatilBiotech: Downgrades arrive at $GILD https://t.co/5OvX8ZmQPG
RT @Jdalexander64: $GILD cc:
1st Question: On R&D side, what areas most excited about to invest in going forward?
Answer: "...opportunity…
Explore #fundamental numbers and pros and cons for $GILD https://t.co/IFnkAQiwhE
$GILD PT lowered to $79 from $87 at Baird
I feel the need to share this chart once again with you all.
Print it and keep it nearby. Understand why are breakt… https://t.co/QSwXoB70fR
Gilead Sciences $GILD PT Lowered to $79 at Baird https://t.co/BpCri1lcBZ
#TRADING US PM Gapers $AAPL $ALV $MA $NVO $IAC $EVTC $BTI $RIO $FCAU $BUD $FTI $BBL $TS $STM $GLD $X $FXI $SNY… https://t.co/0HjXgNIpOP
RT @adamfeuerstein: $GILD ‘trough year’ looking harder to dig out from after miserable first quarter https://t.co/5gQlwcQvjh
Gilead Sciences Receives a Buy from Maxim Group $GILD https://t.co/zFKebUOjTn
$GILD LEERINK-- not cheap enough yet ! Q1 falls short & pipeline depends on crowded RA, price target $80 to $72